chronic kidney disease

Deciphering Healthcare Costs in Type 2 Diabetes and Incident CKD: A Latent Class Trajectory Analysis in Hong Kong

By MedXY 03/26/2026

A longitudinal study using Latent Class Analysis identifies four distinct phenotypes of T2D patients developing CKD, highlighting young-onset and middle-aged low-comorbidity groups as primary drivers of healthcare costs.

Clinical Updates Diabetes & Endocrinology Nephrology news

Healthcare Economic Trajectories in Type 2 Diabetes and Incident CKD: Insights from a Latent Class Analysis in Hong Kong

By MedXY 03/22/2026

This review analyzes a latent class trajectory study identifying four clinical phenotypes of T2D-related CKD, revealing that young-onset patients incur the highest longitudinal healthcare costs.

Cardiology Clinical Updates news

Interaction Between SGLT2 Inhibition and Dietary Sodium: Insights from the CREDENCE Trial Post Hoc Analysis

By MedXY 03/15/2026

This post hoc analysis of the CREDENCE trial reveals that low-normal sodium intake increases cardiovascular risk in T2D and CKD, a risk significantly mitigated by canagliflozin, while renal protection remains consistent across sodium intake levels.

Clinical Updates Diabetes & Endocrinology Nephrology news

SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 Diabetes: A Comparative Effectiveness Review

By MedXY 03/14/2026

This review synthesizes evidence comparing SGLT2 inhibitors and GLP-1 receptor agonists, highlighting a significant reduction in chronic kidney disease and acute kidney injury risks associated with SGLT2i initiation.

Clinical Updates Neurology news

Precision Diagnostics in Alzheimer’s Disease: Optimizing Plasma p-tau217 Cutoffs for Patients with Comorbidities

By MedXY 03/10/2026

This review synthesizes evidence on the impact of kidney function, BMI, and anemia on plasma p-tau217 diagnostic accuracy, advocating for subgroup-specific cutoff strategies to improve clinical outcomes.

Diabetes & Endocrinology Nephrology news

Renal Function and Metabolic Risk: Reduced eGFR Does Not Independently Increase DKA Risk in Type 1 Diabetes

By MedXY 03/07/2026

A landmark 35-year analysis of DCCT/EDIC data demonstrates that a reduced estimated glomerular filtration rate (30–90 mL/min/1.73 m2) is not an independent risk factor for diabetic ketoacidosis, providing a clearer safety framework for the use of SGLT inhibitors in type 1 diabetes.

Cardiology Clinical Updates news

Mechanistic Insights into APOL1-Mediated Hypertension: The STING-Endothelin 1 Axis as a Therapeutic Target

By MedXY 03/02/2026

This review synthesizes findings on how APOL1 risk variants (G2) drive hypertension and kidney damage through cell-specific mechanisms involving STING activation and endothelin-1 production, offering new precision medicine pathways for high-risk populations.

Diabetes & Endocrinology Nephrology news

SGLT2 Inhibitors for All? Meta-Analysis Confirms Broad Clinical Benefits Regardless of Diabetes or Albuminuria Levels

By MedXY 02/09/2026

A large-scale meta-analysis reveals that SGLT2 inhibitors significantly reduce kidney disease progression, AKI, and hospitalizations in patients with CKD, independent of diabetes status or baseline albuminuria.

Diabetes & Endocrinology Nephrology news

SGLT2 Inhibitors Provide Robust Kidney Protection Across All Stages of CKD and Levels of Albuminuria: Evidence from the SMART-C Meta-Analysis

By MedXY 02/09/2026

A meta-analysis of over 70,000 participants confirms that SGLT2 inhibitors significantly reduce chronic kidney disease progression regardless of baseline kidney function or albuminuria levels, supporting their use even in patients with Stage 4 CKD or minimal protein excretion.

Nephrology news Public Health

Beyond the Plate: Mediterranean Lifestyle as a Potent Shield Against Chronic Kidney Disease

By MedXY 02/05/2026

A large-scale prospective study from the UK Biobank reveals that a comprehensive Mediterranean lifestyle—integrating diet, physical activity, and social connectivity—significantly reduces the risk of incident chronic kidney disease by up to 35%.

Nephrology news Public Health

Holistic Mediterranean Lifestyle Linked to 35 Percent Lower Risk of Incident Chronic Kidney Disease

By MedXY 02/04/2026

A large-scale prospective study from the UK Biobank reveals that high adherence to a Mediterranean lifestyle, including diet, physical activity, and social habits, significantly reduces the risk of developing chronic kidney disease over an 11-year follow-up period.

Diabetes & Endocrinology Nephrology news

Beyond Insulin: GLP-1 and SGLT2 Inhibitor Combination Therapy Targets Obesity and Kidney Disease in Type 1 Diabetes

By MedXY 02/04/2026

A pilot study shows that combining GLP-1 analogues and SGLT2 inhibitors with lifestyle changes significantly reduces body weight and albuminuria in overweight Type 1 diabetes patients with CKD, though glycemic and blood pressure improvements remain elusive.

Diabetes & Endocrinology Nephrology news

GLP-1 Receptor Agonists Significantly Reduce MACE Risk Across the CKD Spectrum, Yet Prescription Rates Remain Suboptimal

By MedXY 02/03/2026

Recent data highlights that GLP-1 receptor agonists (GLP1-RAs) reduce cardiovascular risk in patients with chronic kidney disease (CKD), yet real-world prescription rates remain alarmingly low despite these proven benefits across various stages of renal impairment.

Cardiology Diabetes & Endocrinology Nephrology news

Oral Semaglutide Slows eGFR Decline in Patients with Type 2 Diabetes and High Cardiovascular Risk: Insights from the SOUL Trial

By MedXY 02/02/2026

The SOUL trial demonstrates that oral semaglutide significantly slows the annual decline of estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes and cardiovascular disease, despite not meeting the primary composite kidney endpoint in a population with preserved baseline renal function.

Cardiology Nephrology news

Complete Revascularization Benefits Older MI Patients Regardless of Renal Function: Insights from the FIRE Trial

By MedXY 01/17/2026

A sub-analysis of the FIRE trial demonstrates that physiology-guided complete revascularization significantly reduces major adverse cardiovascular events in patients aged 75 and older, irrespective of baseline kidney function, without increasing the risk of contrast-associated acute kidney injury.

Cardiology Nephrology news

Finerenone Extends Cardiorenal Protection Across the Kidney Risk Spectrum in HFmrEF and HFpEF: Insights from FINEARTS-HF

By MedXY 01/16/2026

A prespecified analysis of the FINEARTS-HF trial demonstrates that the mineralocorticoid receptor antagonist finerenone consistently reduces cardiovascular death and heart failure events in patients with HFmrEF/HFpEF, regardless of baseline KDIGO kidney risk category, while maintaining a manageable safety profile.

Cardiology Nephrology news

Interleukin-6 Inhibition: A New Frontier in Reducing Residual Cardiovascular and Renal Risk

By MedXY 01/16/2026

Recent clinical evidence identifies Interleukin-6 (IL-6) as a critical driver of cardiovascular events. The ZEUS trial and recent LoDoCo2 analyses suggest that targeting IL-6 with ziltivekimab may significantly reduce risk for patients with chronic kidney disease and elevated lipoprotein(a).

Nephrology news Public Health

Protecting Your Kidneys and the Planet: The Impact of the Planetary Health Diet on Chronic Kidney Disease

By MedXY 01/11/2026

A large-scale study using UK Biobank data reveals that adhering to a Planetary Health Diet significantly lowers the risk of chronic kidney disease, emphasizing the dual benefits of plant-forward, sustainable eating for both personal health and environmental preservation.

Nephrology news Public Health

Adherence to the Planetary Health Diet Linked to Significantly Lower Risk of Chronic Kidney Disease, with Stronger Benefits for Women

By MedXY 01/11/2026

A large-scale multi-cohort study involving nearly 190,000 participants reveals that the EAT-Lancet reference diet, measured by the Planetary Health Diet Index, reduces the risk of incident chronic kidney disease, particularly among women, across diverse ethnic populations.

Nephrology news Public Health

Saving the Planet, One Kidney at a Time: The Power of the Planetary Health Diet

By MedXY 01/11/2026

Recent research from the UK Biobank reveals that a sustainable, plant-forward diet can lower chronic kidney disease risk by 26%, offering a dual solution for environmental and personal health.